Management of factor VII‐deficient patients undergoing joint surgeries – preliminary results of locally developed treatment regimen. (30th July 2012)

• Record Type: Journal Article
• Authors: Windyga, J.; Zbikowski, P.; Ambroziak, P.; Baran, B.; Kotela, I.; Stefanska‐Windyga, E.
• Is Part Of: Haemophilia. Volume 19:Number 1(2013:Jan.)
• Page Start: 89
• Page End: 93
• Publication Date: 2012-07-30
• Subjects: Hemophilia -- Periodicals; 616.1572005
• DOI: 10.1111/j.1365-2516.2012.02921.x
• Languages: English
• ISSNs: 1351-8216

Abstract

<abstract abstract-type="main" id="hae2921-abs-0001"> <title>Summary</title> <p>Inherited factor VII (FVII) deficiency is a rare coagulation disorder with variable haemorrhagic manifestations. In severely affected cases spontaneous haemarthroses leading to advanced arthropathy have been observed. Such cases may require surgery. Therapeutic options for bleeding prevention in FVII deficient patients undergoing surgery comprise various FVII preparations but the use of recombinant activated factor VII (rFVIIa) seems to be the treatment of choice. To present the outcome of orthopaedic surgery under haemostatic coverage of rFVIIa administered according to the locally established treatment regimen in five adult patients with FVII baseline plasma levels below 10 IU dL<sup>−1</sup>. Two patients required total hip replacement (THR); three had various arthroscopic procedures. Recombinant activated factor VII was administered every 8 h on day of surgery (D0) followed by every 12–24 h for the subsequent 9–14 days, depending on the type of surgery. Factor VII plasma coagulation activity (FVII:C) was determined daily with no predefined therapeutic target levels. Doses of rFVIIa on D0 ranged from 18 to 37 μg kg<sup>−1</sup> b.w. and on the subsequent days – from 13 to 30 μg kg<sup>−1</sup> b.w. Total rFVIIa dose per procedure ranged from 16 to 37.5 mg, and the total number of doses per procedure was 16–31. None of our patients developed excessive bleeding including those in whom FVII:C trough levels returned nearly to the baseline level on the first post‐op day. Preliminary results demonstrate that rFVIIa administered according to our treatment regimen is an effective and safe haemostatic agent for hypoproconvertinaemia patients undergoing orthopaedic surgery.</p> </abstract>